STUDY QUESTION: Are fetal fraction, test failure rate and positive predictive value (PPV) of cell-free fetal DNA (cffDNA) testing different in singleton IVF conceptions compared to spontaneous conceptions?
Introduction
In 1997, Lo et al. first described the presence and measurability of cellfree DNA in maternal blood and subsequently reported that levels of cell-free fetal DNA (cffDNA) were increased in pregnant women carrying fetuses with trisomy 21 (Lo et al., 1997 (Lo et al., , 1999 . There has been recent clinical introduction of cffDNA testing to screen for common fetal chromosomal abnormalities, with studies reporting its use in an Australian setting (Hui et al., 2015; McLennan et al., 2016) . Given the high detection rate for trisomy 21 (Gil et al., 2017) , cffDNA testing has become increasingly popular and is recommended for both high-risk and general obstetric populations (Salomon et al., 2017 ; American College of Obstetricians and Gynecologists Committee on Genetics, 2012).
Cell-free 'fetal' DNA originates from the placenta, and increased amounts are shown to correlate with larger placental mass (Ohashi et al., 2002; Wataganara et al., 2005) . The proportion of cffDNA in relation to maternal cell-free DNA levels in a blood sample is known as fetal fraction. Increasing fetal fraction is associated with higher test sensitivity and positive predictive value (PPV) (Porreco et al., 2014) . Current quantification demonstrates median fetal fraction of~11% at time of testing . While some laboratories do not report fetal fraction results, others report the test as failed if fetal fraction is below 4% (Ashoor et al., 2012b) . Fetal fraction increases with advancing gestational age, varies according to ethnicity, and is lower in women of increased BMI and in pregnancies conceived by IVF (Ashoor et al., 2012a (Ashoor et al., , 2013 Revello et al., 2016) .
Traditional methods of aneuploidy screening have a poorer performance in IVF conception as alterations in the levels of placental serum markers lead to an increased false positive rate (FPR), and as a result, there is increased uptake of invasive testing in this population (Amor et al., 2009; Maymon and Jauniaux, 2002; Raty et al., 2002) . There is high demand and uptake of cffDNA testing in the IVF population where the rate of aneuploidy is higher (Olson et al., 2005) . Furthermore, women who conceive using IVF have increased anxiety and place increased value on their pregnancy, wishing to avoid invasive tests that pose a small risk of procedure related miscarriage (Darwiche et al., 2014; Akolekar et al., 2015) .
Robust evidence of the efficacy of cffDNA testing in IVF conception is warranted as it is clinically performed in the absence of large validation studies in this specific population. Given the effect of IVF conception on placental serum markers (Raty et al., 2002; Amor et al., 2009; Scott et al., 2017) , there may be a similar effect on cffDNA. If indeed fetal fraction is lower in IVF conceptions, the expected consequence of this is higher test failure rate. Current literature on the effect of IVF conception on cffDNA testing characteristics is limited and inconclusive (Pan et al., 2005; Lambert-Messerlian et al., 2014) . Data regarding IVF conception can be found within general or high-risk population studies, but are not considered separately (Bianchi et al., 2012; Bevilacqua et al., 2015; Revello et al., 2016; Sarno et al., 2016; Tan et al., 2016) .
The aim of this study is to compare fetal fraction, test failure rate and PPV of cffDNA testing in pregnancies conceived spontaneously and through IVF, and to investigate the effect of IVF modalities on these test characteristics.
Materials and Methods

Study population
This was a single-center, retrospective cohort study where singleton pregnancies underwent cffDNA screening for trisomies 21, 18, 13 and sex chromosome aneuploidies (SCA) from 10 weeks' gestation. All cases of spontaneously conceived and IVF pregnancies were collected consecutively between April 2013 and November 2016 at a private obstetric and gynecological ultrasound clinic in Melbourne, Australia. Minors (<18 years of age), multiple pregnancies, cases of conception by ovulation induction alone or where cffDNA testing was not performed (because of missed miscarriage, vanishing twin, poor blood collection or preference for immediate invasive testing) were excluded from analysis.
Procedure and data collection
All patients were referred by their treating doctor for cffDNA testing and blood samples were collected onsite. Pre-test counseling was provided and informed consent was obtained. cffDNA testing was performed as a primary screening test (for maternal preference, advanced maternal age or where a prior pregnancy was affected by fetal aneuploidy), or secondary to a high-risk first or second trimester screening result, the presence of markers of aneuploidy or fetal abnormalities by ultrasound.
Women who opted to use cffDNA testing as a primary screening test before 12 weeks' gestation undertook ultrasound prior to blood sampling to confirm fetal number, viability and gestational age. They were subsequently advised to return for fetal structural assessment between 12 and 13 + 6 weeks' gestation.
Demographic information and medical history, including maternal age, weight, height, BMI, ethnicity and method of conception were recorded. For women conceiving by IVF, further information was collected regarding specific IVF modalities.
Written informed consent was provided to perform cffDNA testing, and 20 mL samples of maternal blood were analyzed by Ariosa Diagnostics, Inc., using the Harmony ® Prenatal Test platform, in the United States of America (San Jose, CA, USA) or Australia (Douglass Hanly Moir, Queensland; Australian Clinical Labs, Victoria) as previously described (Sparks et al., 2012a (Sparks et al., , 2012b . Results were returned for pregnancy management and test characteristics were documented. Risk scores for aneuploidy were reported as percentages ranging from <0.01 to >99.9%, or were inconclusive and no report was issued. Fetal fraction was reported as a percentage if >4%. In samples where fetal fraction was <4%, the laboratory did not generate a risk assessment.
All women who received a test failure were offered repeat cffDNA testing and to simultaneously collect bloods for first trimester combined screening (FTCS), including assessment of free beta hCG (free ß-hCG) and pregnancy associated plasma protein A (PAPP-A), and arrangement of ultrasound assessment of nuchal translucency and fetal anatomy. Further genetic counseling was provided for those with high-risk cffDNA testing results, and invasive testing (by chorionic villus sampling [CVS] or amniocentesis) was offered in consultation with their referring doctor. If definitive prenatal testing was undertaken, fetal chromosome analysis was performed by quantitative fluorescent in-situ hybridization (FISH) plus conventional karyotyping or microarray analysis. Final aneuploidy diagnosis was by pre-or post-natal karyotype and/or phenotype at birth for trisomy 21, trisomy 18 and trisomy 13. For sex chromosome aneuploidy, the final diagnosis was by pre-or post-natal karyotype. Final pregnancy outcomes in low-risk cases and placental weight at birth were not available. 
Ethical approval
Statistical analysis
The main outcome measure was failure rate of the test in IVF and spontaneously conceived pregnancies. Secondary outcomes were fetal fraction values of each group, fetal fraction in different modalities of IVF, and PPV of high-risk results.
Continuous variables were expressed as mean and SD for normally distributed data and as median and interquartile range (IQR) for non-normally distributed data. Categorical variables were presented as absolute values and percentages. Differences between the groups were compared using Student t test or Mann-Whitney U test for normally and non-normally distributed data, respectively. Differences in proportions were compared using ChiSquare or Fisher's exact test. All tests were two-tailed and a significance level of 5% was adopted.
Fetal fraction was logarithmically transformed to make its distribution Gaussian and univariate and multivariate truncated linear regression analyses were performed to identify which of the maternal characteristics and IVF modalities were predictors of fetal fraction values (lower fetal fraction limit truncated at 4% as values below this threshold were not reported and led to inconclusive results). Associations between gestational age, BMI and fetal fraction were represented in scatterplots with lines of best fit.
To compensate for the potential effect of missing data for IVF modalities, linear regression-based sensitivity analysis was conducted using pooled results from a multiple imputed strategy (M = 10) (Carpenter et al., 2007) .
Multiple logistic regression was used to determine the effect of maternal characteristics and IVF modalities on test failure rate after first sampling and adjustment for confounders (i.e. gestational age).
Statistical analysis was performed using SPSS 24.0 ® (SPSS Inc., Chicago, IL, USA).
Results
A total of 5625 singleton pregnancies had cffDNA testing performed and were included in the analysis. Of those, 4633 (82.4%) were conceived spontaneously and 992 (17.6%) by IVF. IVF characteristics were available in 782 cases; the other 210 cases had IVF treatment at a different center, and data on IVF modalities were either unavailable or missing at random. Baseline characteristics of the study population are shown in Table I . Primary use of cffDNA testing was somewhat more frequent in IVF (95.1%) compared with spontaneous conceptions (92.6%, P < 0.001). Advanced maternal age was a more common indication for primary test use in IVF (62.8%) than in spontaneous conceptions (41.7%, P < 0.001) and maternal preference was a more common reason for testing in spontaneous (56.3%) than in IVF conceptions (34.8%, P < 0.001).
East Asian and South Asian ethnicities, earlier gestational age, increased BMI and IVF conception were independent predictors of lower fetal fraction (Table II) . Relationships between gestational age, BMI and log 10 fetal fraction are illustrated in Fig. 1 .
Median fetal fraction was lower in IVF than in spontaneous conceptions (10.3 versus 11.9%, P = 0.005) and these differences remained statistically significant when adjusted for gestational age, maternal age, ethnicity and BMI. Differences in fetal fraction between study groups and IVF modalities are shown in Table III . Of the IVF modalities, donor oocyte use and hormone treatment were significantly associated with lower fetal fraction in the univariate analysis, but only donor oocyte use remained as an independent predictor in the multivariate analysis. There were no significant differences between the results of the original dataset when compared to the pooled results obtained in the sensitivity analysis.
Although they remained low, test failure rates were higher in IVF than in spontaneous conceptions, both after first sampling (5.2% [95% CI 4.0-6.9%] versus 2.2% [95% CI 1.8-2.6%], P < 0.001) and overall (2.4% [95% CI 0.5-21.0%] versus 0.7% [95% CI 1.6-3.6%], P < 0.001). In the logistic regression analyses, increased BMI and IVF conception were significant predictors of test failure in singleton pregnancies when adjusted for other variables such as gestational age (Constant −7.802, B values 0.148 and 0.746 for BMI and IVF, respectively, all P < 0.001). None of the IVF modalities were found to be predictive of test failure.
All cases of test failure after first sampling had a redraw performed (100.0%) and the most common reason for test failure in both groups was due to low fetal fraction.
No false positives results occurred for cases at high-risk for trisomy 21, in either IVF or spontaneously conceived pregnancies, but PPV for trisomy 18, trisomy 13 and SCA were lower in IVF than in spontaneous conceptions (Fig. 2 and Supplementary Table SI). Overall PPV of cffDNA testing was lower in IVF conception compared to spontaneous conception (28.6 versus 73.4%, P = 0.002). 
Discussion
Principal findings
The findings of lower fetal fraction, increased test failure rate and decreased PPV in IVF compared with spontaneous conceptions have implications for pre-test counseling provided to women conceiving by IVF. To the best of our knowledge, this is the largest and most extensive study to date on the characteristics of cffDNA testing in IVF conceptions.
Previous studies have reported similar findings that IVF conception, increased BMI, earlier gestational age and South Asian ethnicity are significant predictors of lower fetal fraction (Zhou et al., 2015; Revello et al., 2016) . The additional finding that East Asian ethnicity is also a significant predictor of lower fetal fraction is likely the result of a larger proportion of this ethnicity in our study population and has not been previously reported.
The reduced fetal fraction identified in IVF conceptions suggests that an element of the process (possibly the effect of hormone treatment or impaired placentation) affects production of cffDNA. Positive linear correlation between amounts of placental proteins (free β-HCG, PAPP-A, placental growth factor [PlGF] ) and fetal fraction has been shown previously . Increased amounts of these placental proteins are associated with larger placental mass (Metzenbauer et al., 2001) , and therefore lower fetal fraction in IVF conception may be a consequence of smaller placental mass. Furthermore, the finding of an association between donor oocyte use and lower fetal fraction may be the result of poorer HLA compatibility of the non-self 'transplant' fetus (van der Hoorn et al., 2010), leading to poorer placentation (100% non-self in cases of oocyte donation, in comparison to 50% non-self when own oocyte is used). An association of low fetal fraction with infertility itself cannot, however, be excluded.
An alternative explanation could be that maternal cffDNA concentration increases to cause a relative decrease in fetal fraction. This may be the result of increased inflammation and endothelial damage in women conceiving with IVF (Lee et al., 2015) .
Indeed, recent studies have shown significantly increased rates of preeclampsia among women who had a failed cffDNA test (Chan et 2017), and a significant association between fetal fraction on cffDNA testing and first trimester predictive markers for pre-eclampsia (Rolnik et al., 2018) , which is in keeping with the possibilities of reduced placental mass, inflammation and endothelial dysfunction in these cases. The association between IVF conception and increased test failure rate has been published previously , however this study is the first to describe comparative failure rates. Inherently, the effect of IVF conception on lowering fetal fraction determines this increased test failure rate.
The PPV for individual aneuploidies are similar to those calculated in the literature (Petersen et al., 2017) . The results identify that cffDNA testing in IVF conception is accurate for trisomy 21 alone, but has a poorer predictive value in those women at high-risk for trisomy 18, trisomy 13 and SCA as compared to cffDNA testing in spontaneously conceived pregnancies. Low PPV values are expected in diseases with low prevalence and caution is needed when interpreting these results given the small numbers.
Clinical implications
There is now evidence to support and refine the continued use of cffDNA testing in pregnancies conceived using IVF. Lower fetal fraction leads to lower positive and negative likelihood ratios for these risk calculations (Wright et al., 2015) . However, from a clinical perspective, we are most interested in the fundamental effect it has on increasing test failure rate. Women conceiving with IVF who choose to have cffDNA testing for aneuploidy screening need to be made aware of this limitation, but delaying the test does not seem appropriate as results will be obtained in 95% of the cases after the first attempt. The consequence of test failure is increased wait time for a result to make timely pregnancy management decisions, and secondly, heightened maternal anxiety. Alternative screening by FTCS and/or ultrasound should be used following test failure, alongside any redraw, in anticipation of a repeat failed result.
The implication of decreased PPV for trisomies 18, 13 and SCA in IVF conception is two-fold. Firstly, caution is recommended when facing a high-risk result for trisomy 18 or trisomy 13, particularly in the absence of ultrasound findings. The poor predictive values for these conditions, and for SCA, create significant anxiety which can remain even following reassurance of normality (Hodgson et al., 2010) . Secondly, more women are offered invasive testing, which is associated with a small increase in miscarriage (Akolekar et al., 2015) . CVS is generally undertaken for instances of high-risk result for trisomy 21, as the predictive value is high. For trisomies 18 and 13 high-risk results, in the absence of ultrasound features, amniocentesis is usually preferred, in order to avoid false positive results of invasive testing due to confined placental mosaicism. As there are often no phenotypic abnormalities in fetuses with SCA and placental mosaicism is more common for sex chromosomes than for autosomes, ultrasound is unreliable and amniocentesis or post-natal karyotype can be offered to those women with high-risk result (Kornman et al., 2017) .
Study limitations
IVF details were unascertainable for 210 cases, as the information was not available through our data collection points. Consequently, we presented trimmed data for descriptive analysis of IVF modalities, and linear-regression based multiple imputation was performed for regression analysis of IVF modalities using pooled results. Reassuringly, regression analysis without the imputed data found similar results. The cause of infertility and the results of PGS were not made available to the ultrasound clinic either.
First trimester biochemical markers (free ß-hCG, PAPP-A and PlGF) were not routinely measured in our study due to the fact that patients undergoing cffDNA testing do not have first trimester placental biochemistry routinely analyzed. Nevertheless, the evident association of fetal fraction with biochemical placental markers has been shown previously in the literature Rolnik et al., 2018) .
Inability to karyotype some cases at high-risk for SCA, due to patients' choice, and the occurrence of miscarriages and terminations, resulted in the exclusion of high-risk cases when calculating PPV. Additionally, ascertainment of outcomes in all cases and placental weight at birth were not available as part of this study. Procurement of these outcomes would be useful to calculate true test performance, such as sensitivity and false negative rate. The final outcome as to the occurrence of live birth or termination of the pregnancy in cases with high-risk results was not in the scope of this study, which examined specifically the PPV of the test in these cases.
Conclusions
Most (97.6%) of cffDNA tests on IVF pregnancies will be provided with a result after one or two attempts but the failure rate is higher, fetal fraction is lower and PPV for trisomies 18, 13 and SCA is decreased in IVF pregnancies when compared to those conceived spontaneously. These limitations should be taken into account during pre-test counseling in pregnant women who conceive with IVF. Positive results for conditions other than trisomy 21 should be interpreted with caution and require a detailed ultrasound examination and specialist counseling. Further research to investigate the effects of IVF conception on cell-free DNA production is needed.
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